tiprankstipranks
Trending News
More News >

Evogene’s Lavie Bio Retains Tech Amid Corteva Exit

Evogene’s Lavie Bio Retains Tech Amid Corteva Exit

Evogene (EVGN) has released an update.

Confident Investing Starts Here:

Evogene’s subsidiary, Lavie Bio, faces a strategic shift as Corteva Agriscience terminates their licensing agreement for bio-fungicide candidates. Despite this setback, Lavie Bio will retain rights to the technology and plans to advance its bio-fungicide pipeline independently. Other collaborations between Lavie Bio and Corteva remain unaffected.

For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App